arcutis biotherapeutics eczema treatment cream roflumilast met primary endpoints
Published 1 year ago • 408 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
3:57
top medical news 21.09.2023
-
2:35
monoclonal antibody therapy treatment for moderate to severe atopic dermatitis shows promise
-
2:52
how to use dermatoscopic decision algorithms to assess pigmented skin | prof cliff rosendahl
-
20:06
radiation dermatitis
-
0:53
eczema & dermatitis range - australia
-
1:54:55
idef educational series beyond the surface exploring topical roflumilast
-
6:02
atopic dermatitis: beyond scratching the surface
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
3:48
how and when to use betamethasone? (betnelan, celestone and diprosone) - doctor explains
-
12:59
atopic dermatitis: immunology and treatment targets, part 1
-
1:59
skin biomarkers predict development of atopic dermatitis in infancy
-
3:24
systemic treatments for eczema (part 1)
-
1:07
biosimilar medicines changing psoriasis care - peter van de kerkhof, international psoriasis council
-
5:01
microbiome hackathon: dysbiosis of skin microbiota in psoriatic patients: by aya and zoran
-
2:28
safety, efficacy and drug survival of biologics and biosimilars, a. egeberg et al
-
0:52
how i treat: seborrhoeic dermatitis
-
4:58
psoriasis management: utilization and dosing patterns of biologic therapies, i.y.k. iskandar et al